5-azacytidine + nivolumab

A combination therapy consisting of 5-azacytidine, a hypomethylating agent that inhibits DNA methyltransferase, and nivolumab, a monoclonal antibody targeting the PD-1 receptor. This combination aims to enhance anti-tumor immune responses by both altering cancer cell epigenetics and blocking immune checkpoint inhibition. ## Clinical Applications The combination is being investigated in several conditions: - **Angioimmunoblastic T-cell lymphoma (AITL)**: A study reported an overall response rate of 78%, including 44% partial responses and 33% complete responses in relapsed/refractory AITL patients[1][5]. - **HPV-Associated Head and Neck Squamous Cell Cancer**: Clinical trials are evaluating whether 5-azacytidine makes HPV-associated head and neck cancer more sensitive to nivolumab treatment[2][3][9]. - **Acute Myeloid Leukemia (AML)**: The combination has shown promise in both adult and pediatric patients with relapsed/refractory AML[4][6]. ## Mechanism and Rationale The scientific rationale for combining these agents includes: 1. 5-Azacytidine may "prime" cancer cells by altering their epigenetic profile, potentially making them more recognizable to the immune system. 2. Nivolumab enhances T-cell activity by blocking the PD-1 immune checkpoint. 3. The combination may work synergistically, particularly in cancers with epigenetic dysregulation (such as those with TET2, DNMT3A, or IDH2 mutations)[1][5]. ## Safety Profile The combination appears to be generally well-tolerated: - In AITL patients, the regimen was described as "well-tolerated, especially in elderly patients"[1]. - In pediatric AML patients, the combination showed "an acceptable safety profile" with primarily hematological adverse events and febrile neutropenia being the most common grade 3-4 adverse event[4]. This combination represents an emerging approach that leverages both epigenetic modulation and immune checkpoint inhibition to potentially improve outcomes in difficult-to-treat malignancies.

Brand names

OpdivoVidaza

Other names

nivolumab and azacitidine